BioCentury
ARTICLE | Distillery Therapeutics

Therapeutics: Peroxiredoxin 6 (PRDX6); microRNA 371-3p (miR-371-3p)

September 1, 2016 7:00 AM UTC

Patient sample, cell culture and mouse studies suggest promoting expression of miR-371-3p or inhibiting PRDX6 could help treat Tarceva erlotinib-resistant lung and other cancers. In patients with lung, colorectal, gastric or breast cancer, high tumor expression of PRDX6 correlated with poor survival. In a Tarceva-treated human lung cancer cell line, miR-371-3p decreased PRDX6 expression and viability of cells that acquired resistance to Tarceva compared with a scrambled miRNA, without affecting Tarceva-sensitive cells. In a Tarceva-resistant human lung cancer cell line, siRNA targeting PRDX6 decreased viability. In a xenograft mouse model of Tarceva-resistant lung cancer, overexpression of pre-miR-371 in tumors decreased tumor growth and the number of relapsing animals compared with unmodified pre-miR-371-3p expression. Next steps could include testing PRDX6 inhibition and miR-371-3p in models of other Tarceva-resistant cancers...